Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Darunavir/cobicistat - Important Safety Information from Janssen as approved by the HPRA
Notice type:
3rd Party Publications
Date:
25/06/2018
Problem Or Issue:
Important Safety Information communication from Janssen: Increased risk of treatment failure and increased risk of mother-to-child transmission of HIV infection due to low exposure values of darunavir and cobicistat during the second and third trimesters of pregnancy.
Important Safety Information - Darunavir, cobicistat
« Back
Date Printed: 25/04/2024